Episode 568: Lyme Disease Testing Is Failing Patients: Dr. Liz Horn Explains Why (And What Comes Next)
🎙️ Episode Summary: Lyme Testing Is Failing Early Patients
In this critical episode with special guest co-host Ali Moresco, we sit down with Dr. Liz Horn, Principal Investigator of the Lyme Disease Biobank, to break down her latest research:
👉 Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples
This study takes a hard look at the current FDA-cleared Lyme testing system — and the findings are clear:
👉 Most early Lyme disease cases are being missed
Dr. Horn explains why this is happening, what it means for patients, and why clinical judgment — not just testing — must guide early diagnosis and treatment.
🔬 The Study at the Center of This Episode
📄 View Dr. Liz Horn’s Research Publications
📊 Study Focus:
- Compared Standard Two-Tier Testing (STTT) vs Modified Two-Tier Testing (MTTT)
- Used real-world patient samples from early Lyme cases
- Evaluated four FDA-cleared diagnostic algorithms
- Focused primarily on patients within the first ~3 weeks of symptoms
🚨 Key Finding: Early Lyme Testing Is Deeply Flawed
- Only 22–36% of early Lyme cases tested positive
- That means 64–78% of cases were missed
- Most people with early Lyme disease will test negative
📌 Easy-to-share summary for doctors and patients: New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64–78% of Early Cases
🧠 Why These Tests Fail
- Current tests detect antibodies, not the bacteria itself
- The immune system needs time to produce detectable antibodies
- Early infections often test negative because the immune response has not developed yet
- The two-tier system adds additional opportunities for false negatives
👉 Core issue: Testing measures the body’s response, not the infection
⏱️ The Critical Timing Problem
- Within 1 week of symptoms, tests are almost always negative
- Around 2 weeks, detection improves slightly
- After 3–4 weeks, sensitivity increases but is still unreliable
- Testing does not become fully accurate at any point
👉 Key insight: Testing remains inconsistent even after the early window
🎯 Even “Classic” Lyme Cases Are Missed
- Patients with erythema migrans (EM rash) often tested negative
- Very few patients present with a classic bullseye rash
- A visible rash does not guarantee a positive test result
👉 Key takeaway: You can have Lyme and still test negative
⚠️ Major Issue: Test Inconsistency
- The same patient can receive different results depending on the test used
- One algorithm may detect Lyme while another misses it
- Results depend on timing, immune response, and test design
👉 Result: Testing cannot reliably confirm or rule out Lyme disease
🧍♂️ Who Actually Tests Positive?
- Patients with more symptoms were more likely to test positive
- Longer duration of illness increased likelihood of detection
- Stronger immune responses improved test sensitivity
👉 Translation: Testing tends to detect later-stage immune response, not early infection
💊 After Treatment: Testing Becomes Even Less Useful
- This study focused on early Lyme within the first ~3 weeks, where testing already performed poorly
- At approximately 3 months post-treatment, less than 5% of patients who still had an active infection tested positive
- These patients were originally diagnosed with early Lyme and many continued to have symptoms consistent with active or ongoing infection
👉 Why this happens:
- Antibiotics can suppress antibody production
- The immune response may no longer be detectable
- The bacteria may persist in tissues rather than circulating in blood
👉 Critical takeaway:
Patients may still have an active infection or ongoing disease process and test negative
👉 Bottom line:
- Testing is unreliable early in infection
- Testing remains unreliable after treatment
- A negative test does not rule out Lyme disease at any stage
🧬 Another Challenge: Lyme Leaves the Blood
- Borrelia bacteria can move into tissues
- Blood-based tests may miss active infection
- Direct detection becomes more difficult over time
👉 This is why antibody testing is used, despite its limitations
🧩 Bigger Insight From This Study
- Current Lyme testing cannot reliably diagnose early infection
- Diagnosis must include symptoms, exposure history, and clinical judgment
- Over-reliance on testing leads to missed diagnoses and delayed care
🚀 What Comes Next (Hope from the Research)
- Development of direct detection tests that identify the bacteria
- Cell-free DNA testing approaches
- AI and machine learning diagnostics
- Multiplex testing targeting multiple markers
- Urine-based diagnostic innovations
👉 These advances aim to replace outdated antibody-based testing
🧑⚕️ Education Gap (Major Takeaway)
- Many clinicians are not trained on the limitations of Lyme testing
- Negative tests are often incorrectly used to rule out disease
- This contributes to delayed diagnosis and treatment
📚 Resource for clinicians and patients: VectorWise CME – Lyme Disease Education
💡 What This Means for You
- A negative test does not rule out Lyme disease
- Early symptoms are more important than lab results
- Treatment decisions should not rely solely on testing
- Follow-up care remains essential even after treatment
👉 Most important: Trust your symptoms and advocate for care
💚 Final Message
This study confirms what many patients already experience:
- The testing system is flawed
- Early infections are frequently missed
- Patients can remain sick while testing negative
But progress is happening.
👉 Better diagnostics are on the horizon
You are not alone. Your experience is real.Healing is possible.